Clinical Trial Detail

NCT ID NCT03217266
Title MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

sarcoma

Therapies

AMG 232

Age Groups: adult senior

No variant requirements are available.